Immunome, Inc.
IMNM
Rank in Stocks
#5487
Immunome, Inc., a biotechnology company, engages in the discovery, design,... Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Share Price
$19.36
Last synced: 2026-11-09
Market Cap
$2.28B
Change (1 day)
3.47%
Change (1 year)
17.26%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Immunome, Inc. (IMNM)
Category
Healthcare
EPS for Immunome, Inc. (IMNM)
EPS as of June 2026 TTM: $-2.54
According to Immunome, Inc.'s latest financial reports, its current EPS (TTM) is $-2.54. At the end of 2025 the company had an EPS of $-2.43, an increase over its 2024 EPS of $-5.00.
EPS history for Immunome, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.54 | 4.53% |
| 2025 | $-2.43 | -51.40% |
| 2024 | $-5.00 | -7.06% |
| 2023 | $-5.38 | 74.11% |
| 2022 | $-3.09 | 44.39% |
| 2021 | $-2.14 | 26.63% |
| 2020 | $-1.69 | -8.15% |
| 2019 | $-1.84 | -74.37% |
| 2018 | $-7.18 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -716.54% |
US
|
|
| $-7.07 | 178.35% |
US
|
|
| $-5.29 | 108.27% |
AU
|
|
| $12.88 | -607.09% |
BE
|
|
| $21.56 | -948.82% |
NL
|
Questions about Immunome, Inc.'s earnings per share (EPS)
What is Immunome, Inc.'s earnings per share (EPS)?
Immunome, Inc.'s earnings per share (EPS) over the last twelve months is $-2.54, as of Jun 2026.
What was Immunome, Inc.'s earnings per share (EPS) in 2025?
In 2025, Immunome, Inc.'s earnings per share (EPS) was $-2.43, compared with $-5.00 in 2024.
How has Immunome, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Immunome, Inc.'s earnings per share (EPS) was highest in 2020 ($-1.69) and lowest in 2023 ($-5.38).
How does Immunome, Inc.'s earnings per share (EPS) compare with similar companies?
Immunome, Inc.'s earnings per share (EPS) ($-2.54) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.